Outcome of direct-acting antiviral treatment in patients with hepatitis C virus/hepatitis B virus coinfection

Abstract Background Oral direct-acting antiviral (DAA) regimens for chronic hepatitis C virus (HCV) infection have greatly improved treatment efficacy, with sustained virological response (SVR) rates of > 95% HCV monoinfected patients. However, B (HBV)/HCV coinfection is more complex than monoinfection HBV or alone. We evaluated the SVR rate at 12 weeks post-treatment DAAs in patients HCV/HBV and reactivation during 6 months after treatment. Results Among included patients, 191 (95.5%) achieved SVR. Older age, low platelet count, high serum creatinine, higher liver stiffness value measured by fibroscan were predictors failure to achieve The 16 (8%) had significantly ALT creatinine a RNA viral load baseline compared that those without reactivation. Conclusion Patients who received treat showed it important be aware potential risk DAAs.